Analyzing...
Loading company...
No significant concerns identified
Nothing flagged for monitoring
“Operates in Pharmaceuticals — Formulations & API.”
₹3,918 Cr revenue.
COGS 33.6%, employees 17.6%.
“revenues for the quarter were”
“We reiterate our guidance for operating margins between 27 to 29% for FY '26.”
“our guidance continues to be, growing better than the market two to 300 bps”
| KPI | Company | Sector Median |
|---|---|---|
| ROE | 19.8%▲ | 10.5% |
| ROCE | 25.2%▲ | 13.8% |
| Net Margin | 17.7%▲ | 8.7% |
| EBITDA Margin | 28.1%▲ | 16.0% |
| Debt To Equity | 0.00x▼ | 0.21x |
| Rev Growth 3yr | 17.1%▲ | 5.8% |
| EPS Growth 3yr | 19.3%▲ | 3.6% |
| (₹ Cr) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹4,193 Cr +7.0% | ₹3,918 Cr +12.5% | ₹3,484 Cr +10.6% | ₹3,149 Cr +29.9% | ₹2,424 Cr +18.7% | ₹2,043 Cr +15.1% | ₹1,775 Cr +8.0% | ₹1,643 Cr |
| Other Income | ₹63 Cr +63.5% | ₹38 Cr +2.8% | ₹37 Cr +274.9% | ₹10 Cr -74.7% | ₹39 Cr -65.1% | ₹112 Cr +121.8% | ₹51 Cr +22.3% | ₹41 Cr |
| Total Income | ₹4,256 Cr +7.6% | ₹3,956 Cr +12.3% | ₹3,521 Cr +11.5% | ₹3,159 Cr +28.2% | ₹2,463 Cr +14.3% | ₹2,155 Cr +18.1% | ₹1,825 Cr +8.4% | ₹1,685 Cr |
| COGS | ₹1,344 Cr +2.1% | ₹1,317 Cr +11.4% | ₹1,182 Cr +1.2% | ₹1,168 Cr +38.6% | ₹843 Cr +20.2% | ₹701 Cr +11.2% | ₹631 Cr +5.8% | ₹596 Cr |
| ₹3,245 Cr +5.7% | ₹3,069 Cr +10.8% | ₹2,770 Cr +6.4% | ₹2,604 Cr +33.0% | ₹1,959 Cr +25.7% | ₹1,558 Cr +6.2% | ₹1,467 Cr +4.9% | ₹1,398 Cr | |
| Profit Before Tax | ₹1,011 Cr +13.9% | ₹887 Cr +18.1% | ₹752 Cr +35.4% | ₹555 Cr +10.0% | ₹505 Cr -15.4% | ₹597 Cr +71.1% | ₹349 Cr +21.6% | ₹287 Cr |
| ₹257 Cr +12.8% | ₹228 Cr +14.5% | ₹199 Cr +36.9% | ₹145 Cr +22.2% | ₹119 Cr -19.9% | ₹148 Cr +93.9% | ₹77 Cr -17.8% | ₹93 Cr | |
| Net Profit | ₹754 Cr +14.3% | ₹660 Cr +19.4% | ₹553 Cr +34.8% | ₹410 Cr +6.2% | ₹386 Cr -13.9% | ₹449 Cr +64.7% | ₹272 Cr +40.4% | ₹194 Cr |
| Profit (Owners) | ₹754 Cr +14.3% | ₹660 Cr +19.4% | ₹553 Cr +34.8% | ₹410 Cr +6.4% | ₹385 Cr -14.0% | ₹448 Cr +64.7% | ₹272 Cr +40.3% | ₹194 Cr |
| Other Comprehensive Income | ₹33 Cr +287.0% | ₹9 Cr ↑ Recovery | (₹15 Cr) -7.7% | (₹14 Cr) ↓ Decline | ₹4 Cr | ₹0.33 Cr ↑ Recovery | (₹15 Cr) -256.9% | (₹4 Cr) |
| EPS | ₹48.23 | ₹42.37 | ₹35.61 | ₹26.48 | ₹24.93 | ₹28.98 | ₹17.60 | ₹12.09 |
| Diluted Shares | ₹16 Cr | ₹16 Cr | ₹16 Cr | ₹15 Cr | ₹15 Cr | ₹15 Cr | ₹15 Cr | ₹16 Cr |
No related party data available for this company.
This section will be populated when data becomes available.
Disclaimer · The Stock Filter is an information platform, not a SEBI-registered investment adviser. All data, scores, and narratives are generated from public filings and AI analysis — they do not constitute investment advice, recommendations, or endorsements. Always consult a qualified financial adviser before making investment decisions. Past performance does not guarantee future results.
The Exchange had sought clarification from JB Chemicals & Pharmaceuticals Limited for the quarter ended 31-Mar-2026 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requir...
JB Chemicals & Pharmaceuticals Limited has informed the Exchange about Transcript
JB Chemicals & Pharmaceuticals Limited has informed the Exchange about Link of Recording
JB Chemicals & Pharmaceuticals Limited has informed the Exchange about Newspaper advertisement pertaining to financial results for the quarter and year ended March 31, 2026
JB Chemicals & Pharmaceuticals Limited has informed the Exchange about Newspaper advertisement for Postal Ballot
JB Chemicals & Pharmaceuticals Limited has informed the Exchange regarding Notice of Postal Ballot
This is to inform you that the Compensation Committee of the Board of Directors of the Company has, on February 19, 2026, allotted 31,160 fully paid up equity shares of Re. 1/- each of the Company, to...
JB Chemicals & Pharmaceuticals Limited has informed the Exchange regarding Resignation of Mr Himanshu Ranvah as Other of the company w.e.f. February 06, 2026.
JB Chemicals & Pharmaceuticals Limited has informed the Exchange regarding Resignation of Mr Kunal Khanna as Other of the company w.e.f. March 05, 2026.
JB Chemicals & Pharmaceuticals Limited has informed the Exchange that Record date for the purpose of Dividend is 11-Feb-2026.
JB Chemicals & Pharmaceuticals Limited has informed the Exchange that Board of Directors at its meeting held on February 05, 2026, declared Interim Dividend of Rs. 12.70 per equity share.
JB Chemicals & Pharmaceuticals Limited has informed the Exchange about Change in Key Managerial Personnel - Letter of Resignation
JB Chemicals & Pharmaceuticals Limited has informed regarding Disclosure Shifting of Registered Office
JB Chemicals & Pharmaceuticals Limited has informed the Exchange regarding Allotment of 92490 Shares.
JB Chemicals & Pharmaceuticals Limited has informed the Exchange regarding Resignation of Mr Narayan Saraf as Chief Financial Officer of the company w.e.f. January 30, 2026.